Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.58 |
| ▸ | CNR2 | P34972 | 6/20 | 0.48 |
| ▸ | CNR1 | P21554 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26419333 | 1.00 | AHR (0.58) | AHRCNR2CNR1ALDH1A1MEN1 | |
| SCHEMBL26419335 | 1.00 | AHR (0.58) | AHRCNR2CNR1ALDH1A1MEN1 | |
| SCHEMBL26088845 | 0.80 | AHR (0.57) | AHRALDH1A1CYP1A2KMT2AGAA | |
| SCHEMBL26088960 | 0.80 | AHR (0.57) | AHRALDH1A1CYP1A2KMT2AGAA | |
| SCHEMBL26419165 | 0.80 | AHR (0.57) | AHRALDH1A1CYP1A2KMT2AGAA | |
| SCHEMBL26088751 | 0.79 | AHR (0.55) | AHRALDH1A1KDM4EHPGD | |
| SCHEMBL26087999 | 0.78 | AHR (0.87) | AHRALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL26086663 | 0.78 | AHR (0.87) | AHRALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL26089594 | 0.78 | AHR (0.87) | AHRALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL26086722 | 0.75 | AHR (0.68) | AHRALDH1A1KMT2AGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037322-B2 | AHR agonists | ELI LILLY AND COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037322-B2 | AHR agonists | ELI LILLY AND COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037322-B2 | AHR agonists | ELI LILLY AND COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230127797-A1 | AHR AGONISTS | ELI LILLY AND COMPANY | 2023-04-27 | — | — | US | disclosed |
| US-20230127797-A1 | AHR AGONISTS | ELI LILLY AND COMPANY | 2023-04-27 | — | — | US | disclosed |
| US-20230127797-A1 | AHR AGONISTS | ELI LILLY AND COMPANY | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037322-B2 | AHR agonists | AHR, ARNT, RORC | AHR 1/4885CNR2 80/4885CNR1 89/4885 |
| US-20230127797-A1 | AHR AGONISTS | AHR, ARNT, RORC | AHR 1/4885CNR2 80/4885CNR1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.